Organic Anion Transporters

• 

  Subject Areas on Research

  • Clinical application of cardiovascular pharmacogenetics. 
  • Community pharmacists' experience with pharmacogenetic testing. 
  • Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. 
  • Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. 
  • Enteric microbiome metabolites correlate with response to simvastatin treatment. 
  • Genetics of hyperuricemia and gout: implications for the present and future. 
  • Genome-wide study of methotrexate clearance replicates SLCO1B1. 
  • Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. 
  • Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3. 
  • Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. 
  • SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. 
  • SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. 
  • Sodium-hydrogen exchanger regulatory factor-1 interacts with mouse urate transporter 1 to regulate renal proximal tubule uric acid transport. 
  • The SLCO1B1*5 genetic variant is associated with statin-induced side effects. 
  • The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. 
  • The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. 
  • The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion.